Search
Health Topic

Cardiology

cardiology
Cardiac Biomarker Solutions from Roche

In CVD management, early detection and timely initiation of appropriate treatment are crucial. As a market leader in cardiac biomarkers, Roche is committed to continuing cardiology research to advance early diagnosis and help improve clinical decisions.

 

Heart Failure

NT-proBNP is a well-established Heart Failure (HF) biomarker that can accurately provide objective information to support clinical decision-making from diagnosis to monitoring, to deliver improved care for every HF patient.  

NT-proBNP is recognised as the Gold Standard HF biomarker because it is a powerful prognosticator regardless of therapy.7

Learn More

 

Atrial Fibrillation

GDF-15 is the strongest predictor in the ABC bleeding risk score, providing an improved understanding of each patient’s bleeding-risk profile which may help to inform treatment decisions.13

Learn More

 

Acute Coronary Syndrome

cTnT-hs is a highly sensitive test that allows for earlier detection of AMI, facilitating faster triaging for earlier initiation of appropriate therapy.8-10

A joint approach with Troponin T detection at the Point-of-Care can help achieve faster triaging of patients with suspected acute myocardial infarction in pre-hospital care and the emergency room.11,12

Ben Smith

Cardiology  Disease Area Lead

Benjamin Smith BCom, MBA

 

Ben is the Cardiology Disease Area Lead for Roche Diagnostics Australia. Ben has been with Roche for over 5 years in the Cardiac and Critical Care space. His experience as International Product Manager in Switzerland has paved the way for him to return to his home country, taking on the role of Cardiology Disease Area Lead - educating his colleagues and customers alike in the value of cardiac biomarkers for cardiovascular disease.

 

Latest Articles and Resources

...
    ...

     

    Get in touch to find out more about our Cardiac Solutions

    This page is provided as a contact service and does not replace the advice of a physician. Roche cannot respond to questions about general medical information or questions regarding your personal medical condition. Medications and diagnostics products can not be directly ordered through this website. Please note that we do not respond to form letters or e-mail campaigns.

    Form Successfully Submitted!
    Thank you for your submission!
    text
    close

    References

    1. World Health Organization: http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). [Accessed October 2018, 13th]
    2. Roffi, M. et al. (2016). Eur Heart J 37(3), 267-315
    3. Rutten et al. https://ipccs.org/2017/12/10/epccs-practical-guidance-on-heart-failurediagnosis-and-management-in-primary-care/[Accessed on January 2018, 23rd]
    4. Ponikowski et al. (2016). Eur J Heart Fail. 18:891-975
    5. Yancy et al. (2017). Circulation. 136(6):e137-e161
    6. Data on file. Roche Diagnostics International Ltd. 
    7. McKie and Burnett (2016). J Am Coll Cardiol. 68, 2437-2439
    8. Bandstein et al. (2014). J Am Coll Cardiol. 63, 2569-78
    9. Body et al. (2015). Clin Chem. 61, 983-939
    10. Rubini-Giménez et al. (2013). Int J Cardiol. 168, 3896-3901
    11. Roche CARDIAC POC Troponin T- Method Sheet-package insert 
    12. Stengaard et al. (2013). Am J Cardiol. 112, 1361-1366
    13. Hijazi et al. (2016). Lancet. 387, 2302-2311

    Abbreviations

    NT-proBNP: N-terminal prohormone of brain natriuretic peptide; POC: point of care

    09441751001_00000000_02